Frankfurt Stock Exchange

Research project with the University of Bremen started project for the development of magnetic iron oxide particles with improved efficiency promotion by the Ministry in the framework of the “central innovation programme for SMEs (ZIM)” agreed Frankfurt / Berlin, January 31, 2013 – the Nanostart holding MagForce AG (Frankfurt, XETRA: MF6), a leader in the field of nano technology medical technology company with focus on oncology, today announced that with the University of Bremen, Center for environmental research and sustainable technologies, a project for the development of magnetic iron oxide particles with improved efficiency will start. The abdominal cancers such as prostate and pancreatic cancer are can be treated with these new particles more effectively. In addition to a powerful magnetic fluid, a pilot production plant is to be built after the completion of the project. The project is being funded in the framework of the “central innovation programme for SME (ZIM)” of the Federal Ministry of Economics and is set to two years. “We are very pleased with Mr.

Prof. Dr.-ing. Jorg Thoming, an internationally renowned engineering expert as a cooperation partner to win.” The project fits into the new strategy by MagForce, increasingly in the form of external research and development collaborations with academic institutions to carry out their fundamental research”, says Prof. Dr. Hoda Tawfik, COO and co-CEO of the MagForce AG. “In August 2012 we stopped temporarily own early research and development, in order to focus the resources of the company on the establishment of the NanoTherm therapy. With this project the next NanoTherm can be developed generation, which will significantly improve the treatment of abdominal cancers.” Prof.

Dr.-ing. Jorg Thoming commented: “I look forward to the cooperation in the field of nanotechnology with innovative Nano medicine company MagForce. The synergies between our scientists is very promising.” Nano launch: The Nano launch AG is a leading Nanotechnology investment company. The company invested venture capital (venture capital, VC) in young promising nanotechnology companies. Thereby, Nanostart invests globally and at different stages of development. The investments of the company focus on innovative sectors such as Cleantech, life sciences and IT/electronics. Nanostart invests directly in nanotechnology companies, or through regional nanotechnology Fund. The headquarters of nano start AG is Frankfurt am Main. About their involvement in Singapore, which Nanostart Asia Pacific, invests them as partners of the Government of Singapore. MagForce AG: The MagForce AG is a worldwide leading company in the field of nanotechnology-based cancer therapy. The therapy process developed by you, the Nano-cancer therapy, allows the targeted treatment of solid tumors by heat using magnetic nanoparticles. Their medical NanoTherm and NanoActivator(TM) are approved across the EU for the treatment of brain tumors Disclaimer: this release is not a Offer to sell nor a solicitation of an offer to purchase or to subscribe for securities dar. A public offer (IPO) of securities of nano start AG in connection with the listing of shares in the portion of the segment (open market) of the Frankfurt Stock Exchange, the “entry standard” does not take place. This communication presents a securities prospectus. This press release and the information contained therein are intended not for the direct or indirect transfer or within Canada, Australia or Japan. Press contact: Nano start AG Dr. Hans Joachim Durr Head of corporate communications Goethestrasse 26-28 D-60313 Frankfurt am Main, Germany telephone: + 49 (0) 69 21 93 96 111 fax: + 49 (0) 69 21 93 96 150 E-Mail: